Syntara (ASX:SNT) reported that it is developing a topical anti-fibrotic drug candidate, SNT-9465, as part of its expanded skin scarring program, according to a Tuesday Australian bourse filing.
The AU$2 million clinical development plan for SNT-9465, funded from existing cash reserves, is designed to demonstrate the drug's safety and tolerability as well as to study its ability to improve both the appearance and physical properties of hypertrophic scars.
A phase 1a dose escalation study in healthy volunteers will be conducted to determine the optimal dose for complete lysyl oxidase inhibition. This will be followed by an open-label phase 1b extension, which will assess improvements in the appearance and composition of hypertrophic scars that are less than 24 months old, after three months of daily treatment.
It expects the results to come in the first half of 2026.
Meanwhile, The Fiona Wood Foundation and the University of Western Australia will conduct an exploratory clinical trial on keloid scarring and Syntara will provide financial and technical support.
The firm's shares rose 3% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.